<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39323094</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.</ArticleTitle><Pagination><StartPage>e29935</StartPage><MedlinePgn>e29935</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29935</ELocationID><Abstract><AbstractText>Studies have pointed to a decisive role of autoantibodies in the context of sepsis and severe Coronavirus disease 2019 (COVID-19), which itself often fulfills the criteria for sepsis, including dysregulated immune responses and organ dysfunction. To directly compare and further analyze the autoantibody profiles of sepsis patients with and without COVID-19, the luciferase immunoprecipitation systems (LIPS) assay was used to measure the levels of autoantibodies against a variety of clinically relevant cytokines, lung-associated proteins, other autoantigens, and antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, cytokine titers were measured with the LEGENDplex™ Human Antivirus Response Panel. We observed significantly increased levels of autoantibodies in 59% of the COVID-19-Sepsis group compared to 48% of the Sepsis group. Significant differences were identified between the groups for the levels of autoantibodies against gATPase. The cytokine levels of interferon (IFN)-λ1 and IP-10 were higher in the COVID-19-Sepsis group compared to the Sepsis group. Additional correlations between autoantibodies, cytokines and 30-day survival could be demonstrated, suggesting varied underlying pathological mechanisms. Elevated levels of cytokines and autoantibodies may serve as prognostic indicators for the survival probability of sepsis patients, highlighting the intricate relationship between immune responses and patient outcomes in the context of both sepsis and COVID-19.</AbstractText><CopyrightInformation>© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kühn</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3094-9877</Identifier><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinen</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Virology, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for the Research on HIV and AIDS-associated diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Simon T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leibniz Institute of Virology (LIV), Research Unit Emerging Viruses, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocke</LastName><ForeName>Maximilian K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Virus Bioinformatics Center (EVBC), Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todt</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3564-1014</Identifier><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Virus Bioinformatics Center (EVBC), Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burbelo</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinmann</LastName><ForeName>Eike</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziehe</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum (KKB), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koos</LastName><ForeName>Björn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum (KKB), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamzik</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum (KKB), Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putensen</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn (UKB), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarbock</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster (UKM), Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravemann</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jork</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaender</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leibniz Institute of Virology (LIV), Research Unit Emerging Viruses, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Virology and Cell Biology, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SepsisDataNet.NRW and CovidDataNet.NRW research group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P089-23</GrantID><Agency>Ruhr University Bochum FoRUM Forschungsförderung</Agency><Country /></Grant><Grant><Agency>Intramural program of the National Institute of Dental and Craniofacial Research</Agency><Country /></Grant><Grant><Agency>European Regional Development Fund</Agency><Country /></Grant><Grant><Agency>State of North Rhine-Westphalia</Agency><Country /></Grant><Grant><Agency>German Federal Ministry of Education and Research</Agency><Country /></Grant><Grant><GrantID>STE1954/8-1</GrantID><Agency>German Research Foundation</Agency><Country /></Grant><Grant><Agency>VIRus-ALlianz NRW (VIRAL)</Agency><Country /></Grant><Grant><GrantID>76.06.04-20/2024-6626</GrantID><Agency>Ministry of Culture and Science of the State of North Rhine-Westfalia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323094</ArticleId><ArticleId IdType="doi">10.1002/jmv.29935</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265‐269.</Citation></Reference><Reference><Citation>Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID‐19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS‐CoV‐2. Biochimie. 2020;179:85‐100.</Citation></Reference><Reference><Citation>Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID‐19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021;93(4):e12998.</Citation></Reference><Reference><Citation>Mahalingam S, Peter J, Xu Z, et al. Landscape of humoral immune responses against SARS‐CoV‐2 in patients with COVID‐19 disease and the value of antibody testing. Heliyon. 2021;7:e06836.</Citation></Reference><Reference><Citation>Ehrenfeld M, Tincani A, Andreoli L, et al. Covid‐19 and autoimmunity. Autoimmun Rev. 2020;19:102597.</Citation></Reference><Reference><Citation>Manry J, Bastard P, Gervais A, et al. The risk of COVID‐19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci. 2022;119(21):e2200413119.</Citation></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life‐threatening COVID‐19. Science. 2020;370(6515):eabd4585.</Citation></Reference><Reference><Citation>Zhu Z, Cai T, Fan L, et al. Clinical value of immune‐inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020;95:332‐339.</Citation></Reference><Reference><Citation>Del Valle DM, Kim‐Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID‐19 severity and survival. Nature Med. 2020;26:1636‐1643.</Citation></Reference><Reference><Citation>Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID‐19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38‐42.</Citation></Reference><Reference><Citation>Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in COVID‐19 and non‐COVID‐19 ARDS: a systematic review and meta‐analysis. Intensive Care Med. 2021;47:521‐537.</Citation></Reference><Reference><Citation>Shappell CN, Klompas M, Chan C, et al. Use of electronic clinical data to track incidence and mortality for SARS‐CoV‐2‐associated sepsis. JAMA Network Open. 2023;6:e2335728.</Citation></Reference><Reference><Citation>Jensen IJ, Jensen SN, McGonagill PW, Griffith TS, Mangalam AK, Badovinac VP. Autoimmunity increases susceptibility to and mortality from sepsis. Immunohorizons. 2021;5:844‐854.</Citation></Reference><Reference><Citation>Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11:R49.</Citation></Reference><Reference><Citation>Yang Y, Chen J, Yi C, et al. Assessment of serum interleukin‐28 as a biomarker to predict mortality in traumatic patients with sepsis. Cytokine. 2022;157:155959.</Citation></Reference><Reference><Citation>Abouda A, Hajjej Z, Mansart A, et al. Anticardiolipin autoantibodies as useful biomarkers for the prediction of mortality in septic patients. J Immunol Res. 2022;2022:1‐8.</Citation></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis‐3). JAMA. 2016;315:801.</Citation></Reference><Reference><Citation>Burbelo PD, Lebovitz EE, Notkins AL. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl Res. 2015;165:325‐335.</Citation></Reference><Reference><Citation>Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222:206‐213.</Citation></Reference><Reference><Citation>Ferré EMN, Break TJ, Burbelo PD, et al. Lymphocyte‐driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Sci Transl Med. 2019;11(495):eaav5597.</Citation></Reference><Reference><Citation>Burbelo PD, Seam N, Groot S, et al. Rapid induction of autoantibodies during ARDS and septic shock. J Transl Med. 2010;8:97.</Citation></Reference><Reference><Citation>Burbelo PD, Castagnoli R, Shimizu C, et al. Autoantibodies against proteins previously associated with autoimmunity in adult and pediatric patients with COVID‐19 and children with MIS‐C. Front Immunol. 2022;13:1.</Citation></Reference><Reference><Citation>Burbelo PD, Browne S, Holland SM, Iadarola MJ, Alevizos I. Clinical features of Sjögren's syndrome patients with autoantibodies against interferons. Clin Transl Med. 2019;8:1.</Citation></Reference><Reference><Citation>Burbelo PD, Browne SK, Sampaio EP, et al. Anti‐cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010;116:4848‐4858.</Citation></Reference><Reference><Citation>Burbelo PD, Groot S, Dalakas MC, Iadarola MJ. High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in Stiff‐Person syndrome. Biochem Biophys Res Commun. 2008;366:1‐7.</Citation></Reference><Reference><Citation>Thi Nhu Thao T, Labroussaa F, Ebert N, et al. Rapid reconstruction of SARS‐CoV‐2 using a synthetic genomics platform. Nature. 2020;582(7813):561‐565.</Citation></Reference><Reference><Citation>Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ. Antibody profiling by luciferase immunoprecipitation systems (LIPS). J Vis Exp. 2009;32:1549. doi:10.3791/1549</Citation></Reference><Reference><Citation>Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517‐528.</Citation></Reference><Reference><Citation>Zettl F, Meister TL, Vollmer T, et al. Rapid quantification of SARS‐CoV‐2‐Neutralizing antibodies using propagation‐defective vesicular stomatitis virus pseudotypes. Vaccines. 2020;8:386.</Citation></Reference><Reference><Citation>Burman P, Karlsson FA, Lööf L, Szesci PB, Borch K. H+,K‐ATPase antibodies in autoimmune gastritis: observations on the development of pernicious anemia. Scand J Gastroenterol. 1991;26:207‐214.</Citation></Reference><Reference><Citation>Galanopoulos M, Gkeros F, Doukatas A, et al. COVID‐19 pandemic: pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020;26:4579‐4588.</Citation></Reference><Reference><Citation>Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nature Immunol. 2016;17(8):906‐913.</Citation></Reference><Reference><Citation>Malik A, Kanneganti TD. Function and regulation of IL‐1α in inflammatory diseases and cancer. Immunol Rev. 2018;281:124‐137.</Citation></Reference><Reference><Citation>Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high‐dose IV anakinra in severe COVID‐19 lung disease. J Allergy Clin Immunol. 2020;146:213‐215.</Citation></Reference><Reference><Citation>Suzuki H, Ayabe T, Kamimura J, Kashiwagi H. Anti‐IL‐1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects. Clin Exp Immunol. 1991;85:407.</Citation></Reference><Reference><Citation>Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021;18:208.</Citation></Reference><Reference><Citation>Alimohammadi M, Dubois N, Sköldberg F, et al. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proc Natl Acad Sci. 2009;106:4396‐4401.</Citation></Reference><Reference><Citation>Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:403701.</Citation></Reference><Reference><Citation>McNab F, Mayer‐Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87‐103.</Citation></Reference><Reference><Citation>Aggarwal BB. Signalling pathways of the TNF superfamily: a double‐edged sword. Nat Rev Immunol. 2003;3(9):745‐756.</Citation></Reference><Reference><Citation>Hasanvand A. COVID‐19 and the role of cytokines in this disease. Inflammopharmacology. 2022;30:789‐798.</Citation></Reference><Reference><Citation>Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (Foreseeable) future of biological Anti‐TNF alpha therapy. J Clin Med. 2023;12:1630.</Citation></Reference><Reference><Citation>Guo Y, Hu K, Li Y, et al. Targeting TNF‐α for COVID‐19: recent advanced and controversies. Front Public Health. 2022;10:833967.</Citation></Reference><Reference><Citation>Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM‐CSF in severe COVID‐19. Science Immunology. 2021;6(57):eabg9873.</Citation></Reference><Reference><Citation>Leavis HL, van de Veerdonk FL, Murthy S. Stimulating severe COVID‐19: the potential role of GM‐CSF antagonism. Lancet Respir Med. 2022;10:223‐224.</Citation></Reference><Reference><Citation>Domingo P, Mur I, Mateo GM, et al. Association between administration of IL‐6 antagonists and mortality among patients hospitalized for COVID‐19: a meta‐analysis. JAMA. 2021;326:499‐518.</Citation></Reference><Reference><Citation>Onuk S, Sipahioğlu H, Karahan S, et al. Cytokine levels and severity of illness scoring systems to predict mortality in COVID‐19 infection. Healthcare (Basel, Switzerland). 2023;11:387.</Citation></Reference><Reference><Citation>Shahbazi M, Amri Maleh P, Bagherzadeh M, et al. Linkage of Lambda Interferons in Protection Against Severe COVID‐19. J Interferon Cytokine Res. 2021;41:149‐152. https://home.liebertpub.com/jir</Citation></Reference><Reference><Citation>Luo Q, Liu Y, Liu S, Yin Y, Xu B, Cao J. Interleukin 28 is a potential therapeutic target for sepsis. Clin Immunol. 2019;205:29‐34.</Citation></Reference><Reference><Citation>Bunprakob S, Hemachudha P, Ruchisrisarod C, Supharatpariyakorn T, Hemachudha T. IP‐10 and complement activation as friend or foe in COVID‐19. Int J Immunopathol Pharmacol. 2022;36:039463202210962.</Citation></Reference><Reference><Citation>Samaras C, Kyriazopoulou E, Poulakou G, et al. Interferon gamma‐induced protein 10 (IP‐10) for the early prognosis of the risk for severe respiratory failure and death in COVID‐19 pneumonia. Cytokine. 2023;162:156111.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>